Insights from experts on how to best navigate the complexity of NASH clinical trials.
Non-alcoholic steatohepatitis (NASH), a component of metabolic syndrome, is an area of very active clinical development. With no approved therapies to treat NASH, there are more than 130 Phase II or Phase III NASH trials underway or planned.
To help determine the impact of this competitive environment for available and qualified site resources, as well as eligible patients, ICON undertook a global survey of NASH clinical trial sites across 37 different countries.Read the whitepaper
Get insights and feedback from our extensive NASH study experience, and the findings from ICON’s survey of more than 2,000 sites across 30 countries including:
Join Andrew Roche, PhD, a senior member of ICON's NASH team, as he speaks about overcoming the challenges and considerations associated with NASH Clinical Trials and examination of potential strategies to address during trial design or study execution.Access the webinar recording
ICON's Martin Benson provides expert commentary on liver disease and the challenges faced by clinical researchers.
It’s also believed that a high proportion of NASH patients are undiagnosed because the disease is largely symptomless or causes non-specific symptoms until well advanced.
Non-Alcoholic SteatoHepatitis (NASH) is the most severe form of non-alcoholic fatty liver disease (NAFLD).
Discover more solutions and insights from our experts to address the growing unmet clinical need for NASH treatments.